Search

file (10) (1)

OBI Information

News

HOMEWhat’s NewNews

2025.Oct.08

Award & Certification​

OBI Chairman Dr. Kung-Yee Liang Receives the 2024–2025 Presidential Science Prize

2025.Sep.26

Corporate

OBI Invited to Present ADC Technology Platform and Chaired Sessions at Biologics World Korea 2025

2025.Sep.03

Corporate

OBI Pharma and AP Biosciences Sign Technology Collaboration Agreement to Develop Next-Generation ADC

2025.Sep.01

Corporate

OBI Pharma, Inc. Announces Board Resolution for Capital Reduction to Offset Accumulated Losses and Holds Material Information Press Conference

2025.Aug.31

Corporate

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

2025.Jul.22

Corporate

OBI Pharma Showcases Innovative Pipeline, Platforms, and Technologies at BIO Asia–Taiwan 2025
GlycOBI® and HYPrOBI™ Drive the Advancement of Bispecific, Dual-Payload ADCs

2025.Jun.27

Corporate

Innovation in Action: OBI Pharma Sharpens Focus on ADC Products, Platforms, and Out-Licensing
Integrating Product and Platform Capabilities to Drive Global Collaboration

2025.Jun.10

Corporate

OBI Pharma Showcases Next-Generation ADC Development at 2025 World ADC Asia Summit

2025.Jun.06

Corporate

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

2025.May.01

Corporate

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC

Announcements

Latest announcements

Events

Latest events